Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    0.9%
    Check dated 2025-04-16T13:53:40.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.3%
    Check dated 2025-04-09T08:41:39.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    45 days ago
    Change Detected
    Summary
    The status of a previously active entity has been updated to 'Unknown' and is now verified by Jiangsu HengRui Medicine Co., Ltd. This indicates a significant change in the operational status of the entity.
    Difference
    3%
    Check dated 2025-03-03T23:55:54.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T20:37:37.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    5%
    Check dated 2025-02-10T09:41:45.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T07:28:10.000Z thumbnail image

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.